Skip to Main Content

Paper Details

Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma and other solid tumors.
J Immunother Cancer
9
2023
IL-8, IP-10, MSS, MSS mCRC, NK cells, PD-1, Participants, Pixatimod, T cells, TLR9, Toll-like Receptor 9, dendritic cells, immunologically cold cancers, mCRC, mPDAC, metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma, nivolumab, pancreatic ductal adenocarcinoma, participant, participants, pixatimod, plasma IL-6, solid tumors
Author NameAffiliation
Andrew D CloustonRoyal Brisbane and Women's Hospital
Andrew D CloustonRoyal Brisbane and Women's Hospital
  • 1 - 2

Datasets

Release 1.2